Trial Profile

Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 29 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 2302024A (Primary) ; Aromatase inhibitors; Carboplatin; Cyclophosphamides; Docetaxel; Doxorubicin; Epirubicin; Exemestane; Fluorouracil; Letrozole; Paclitaxel; Trastuzumab
Indications Advanced breast cancer; Male breast cancer
Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
Acronyms INDUCT; NEOADJ
Sponsors GlaxoSmithKline; GSK

Most Recent Events

14 May 2019 This trial has been discontinued in UK as per European Clinical Trials Database record.
24 Sep 2014 Status changed from recruiting to discontinued, as per ClinicalTrials.gov record.
29 Apr 2014 New source identified and integrated (M.D. Anderson Cancer Center: 2013-0418).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com